Year All 2026 2025 2024 2023 2022 2021 2020 Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York September 9, 2026 Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York September 3, 2026 Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board August 18, 2026 Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights August 14, 2026 Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston August 10, 2026 Helus Pharma Appoints Michael Halstead as Chief Executive Officer August 3, 2026 Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule July 21, 2026 Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results June 29, 2026 Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering June 25, 2026 Helus Pharma™ Announces US$50 Million Underwritten Offering June 24, 2026
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York September 9, 2026
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York September 3, 2026
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board August 18, 2026
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights August 14, 2026
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston August 10, 2026
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule July 21, 2026
